VU University Medical Center-ko ikertzaileekin lankidetzan egindako argitalpenak (38)

2024

  1. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

    Infection

2023

  1. Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study

    HemaSphere, Vol. 7, Núm. 9, pp. E942

  2. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group

    Cytometry Part B - Clinical Cytometry, Vol. 104, Núm. 1, pp. 27-50

2022

  1. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

    Blood, Vol. 140, Núm. 26, pp. 2773-2787

  2. Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT

    Blood Cancer Journal, Vol. 12, Núm. 9

2021

  1. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

    Journal of Hematology and Oncology, Vol. 14, Núm. 1

  2. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues—Recommendations from the European LeukemiaNet

    Cytometry Part B - Clinical Cytometry

  3. Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

    Leukemia, Vol. 35, Núm. 6, pp. 1745-1750

2020

  1. Core outcome set measurement for future clinical trials in acute myeloid leukemia: The HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting

    Trials, Vol. 21, Núm. 1

  2. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies

    ESMO Open, Vol. 5, Núm. 1

2019

  1. Insights on Multiple Myeloma Treatment Strategies

    HemaSphere, Vol. 3, Núm. 1

  2. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312

  3. Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation

    Haematologica, Vol. 104, Núm. 5, pp. 929-936

  4. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions

    Haematologica, Vol. 104, Núm. 10, pp. 1935-1949

2018

  1. A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma

    Critical Reviews in Oncology/Hematology, Vol. 121, pp. 74-89

  2. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and renal impairment: Results from a phase ii trial

    Journal of Clinical Oncology

  3. Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network

    Leukemia, Vol. 32, Núm. 7, pp. 1542-1560

2017

  1. Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study

    International Journal of Molecular Sciences, Vol. 18, Núm. 4

  2. High-dose therapy and autologous stem cell transplantation in patients with poems syndrome: A retrospective study of the plasma cell disorder sub-committee of the chronic malignancy working party of the European society for blood & marrow transplantation

    Haematologica, Vol. 102, Núm. 1, pp. 160-167

  3. Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group

    Haematologica, Vol. 102, Núm. 2, pp. 308-319